Bass' latest IPR petition targets Eliquis

Hedge fund manager Kyle Bass is challenging a patent on Eliquis apixaban from Bristol-Myers Squibb Co. (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) with an inter partes review (IPR) petition.

The Coalition for Affordable Drugs IX, an entity associated with Bass, filed the petition on Thursday with the U.S. Patent and Trademark Office challenging U.S. Patent No. 6,967,208, which covers Eliquis and expires in 2023. The '208 patent is one of two Orange Book-listed patents covering the direct Factor Xa inhibitor and the last to expire. ...